{"url_path":"/sec/sana/8-k/2026-05-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1770121/0001193125-26-226674-index.html","accession_number":"0001193125-26-226674","cik":"0001770121","ticker":"SANA","issuer_name":"Sana Biotechnology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770121/0001193125-26-226674-index.html","primary_entity_key":"0001770121","primary_entity_name":"Sana Biotechnology, Inc."},"word_count":106,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn May 15, 2026, Sana Biotechnology, Inc. (the “Company”) announced that it had sold an aggregate of 21,607,878 shares of its common stock, for aggregate net proceeds of approximately $69.0 million, pursuant to its amended and restated sales agreement with TD Securities (USA) LLC, acting as sales agent.\n\n \n\n1\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSana Biotechnology, Inc.\n\nDate: May 15, 2026\n \n\n \nBy:\n \n\n/s/ Aaron M. Grossman\n\n \n\n \n\n \nAaron M. Grossman\n\n \n\n \n\n \nExecutive Vice President, Chief Legal Officer\n\n \n\n2"}